Inventiva

Small-molecule therapeutics for MASH/fibrosis

IVA · Nasdaq · France

Share price · IVA

$3.39-1.25 (-26.94%) 3M

close as of 2026-11-18 · 24h delayed · vol 3.5M (1.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when IVA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 2 Nov 2026+4.9%
  2. 21 Oct 2026+8.9%
  3. 9 Oct 2026-4.8%

    Nothing announced by IVA that day or the session before.

  4. 30 Sep 2026+12.2%
  5. 29 Sep 2026-6.8%
  6. 7 Jul 2026+16.9%
  7. 24 Jun 2026-6.7%
  8. 2 Jun 2026-14.3%
  9. 29 May 2026-5.7%
  10. 11 May 2026+8.0%

    Nothing announced by IVA that day or the session before.

Share of unusual movement by asset

For each asset, the share of IVA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Lanifibranor
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—18%
Sessions with no dated event—82%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
Peroxisome proliferator-activated receptors (PPARs) · PPAR (pan-agonist)Small molecule
Type 2 DiabetesMASH / NASH

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$10.0M$98M$100M$50M-$93M operating cash flowreport ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY$19M$119M$30M+ <$0.1M short-term inv.$30M-$88M operating cash flowreport ↗
2022-FY$13M$64M$92M+ $1.1M short-term inv.$14M-$47M operating cash flowreport ↗
2021-FY$5.0M$57M$98M+ $10.0M short-term inv.$15M-$56M operating cash flowreport ↗

Insider transactions

This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 66 reporting institutions held 52.4M shares ($290.1M, 27.1% of shares outstanding).

#InstitutionSharesValue
1SAMSARA BIOCAPITAL, LLC5,194,805$28.8M
2Caligan Partners LP4,974,906$27.6M
3Paradigm Biocapital Advisors LP4,000,000$22.2M
4MILLENNIUM MANAGEMENT LLC2,987,613$16.6M
5Trails Edge Capital Partners, LP2,657,997$14.8M
6FRANKLIN RESOURCES INC2,461,565$13.7M
7SymBiosis Capital Partners, LLC2,354,000$13.1M
8UBS Group AG2,318,693$12.9M
9ADAR1 Capital Management, LLC2,174,398$12.1M
10Polar Capital Holdings Plc2,132,138$11.8M
11ANDERA PARTNERS1,818,181$10.1M
12Yu Fan1,500,000$8.3M
13BOOTHBAY FUND MANAGEMENT, LLC1,470,407$8.2M
14NEA Management Company, LLC1,462,586$8.0M
15Ikarian Capital, LLC1,429,101$7.8M